Search Results - "Merchant, Kalpana"

Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations by Dehay, Benjamin, PhD, Bourdenx, Mathieu, MS, Gorry, Philippe, MD, Przedborski, Serge, Prof, Vila, Miquel, MD, Hunot, Stéphane, PhD, Singleton, Andrew, PhD, Olanow, C Warren, Prof, Merchant, Kalpana M, PhD, Bezard, Erwan, Prof, Petsko, Gregory A, Prof, Meissner, Wassilios G, Prof

“…Summary Progressive neuronal cell loss in a small subset of brainstem and mesencephalic nuclei and widespread aggregation of the α-synuclein protein in the…”
Get full text

LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson’s disease patients by Ysselstein, Daniel, Nguyen, Maria, Young, Tiffany J., Severino, Alex, Schwake, Michael, Merchant, Kalpana, Krainc, Dimitri

“…Mutations in LRRK2 and GBA1 are common genetic risk factors for Parkinson’s disease (PD) and major efforts are underway to develop new therapeutics that target…”
Get full text

Urinary proteome profiling for stratifying patients with familial Parkinson’s disease by Virreira Winter, Sebastian, Karayel, Ozge, Strauss, Maximilian T, Padmanabhan, Shalini, Surface, Matthew, Merchant, Kalpana, Alcalay, Roy N, Mann, Matthias

“…The prevalence of Parkinson's disease (PD) is increasing but the development of novel treatment strategies and therapeutics altering the course of the disease…”
Get full text

Higher Urine bis(Monoacylglycerol)Phosphate Levels in LRRK2 G2019S Mutation Carriers: Implications for Therapeutic Development by Alcalay, Roy N., Hsieh, Frank, Tengstrand, Elizabeth, Padmanabhan, Shalini, Baptista, Marco, Kehoe, Caitlin, Narayan, Sushma, Boehme, Amelia K., Merchant, Kalpana

“…Background LRRK2 mutations are a common cause of dominantly inherited PD. Previous studies showed decreases in urine levels of didocohexaenoyl (22:6)…”
Get full text

Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease by Surface, Matthew, Balwani, Manisha, Waters, Cheryl, Haimovich, Alexander, Gan‐Or, Ziv, Marder, Karen S., Hsieh, Tammy, Song, Linxia, Padmanabhan, Shalini, Hsieh, Frank, Merchant, Kalpana M., Alcalay, Roy N.

“…ABSTRACT Background Biallelic mutations in the GBA1 gene encoding glucocerebrosidase cause Gaucher's disease, whereas heterozygous carriers are at risk for…”
Get full text

Transcriptomic Analysis of Induced Pluripotent Stem Cells Derived from Patients with Bipolar Disorder from an Old Order Amish Pedigree by Kim, Kwi Hye, Liu, Jiangang, Sells Galvin, Rachelle J, Dage, Jeffrey L, Egeland, Janice A, Smith, Rosamund C, Merchant, Kalpana M, Paul, Steven M

“…Fibroblasts from patients with Type I bipolar disorder (BPD) and their unaffected siblings were obtained from an Old Order Amish pedigree with a high incidence…”
Get full text

Quantitative Measurement of Intact Alpha-Synuclein Proteoforms from Post-Mortem Control and Parkinson's Disease Brain Tissue by Intact Protein Mass Spectrometry by Kellie, John F., Higgs, Richard E., Ryder, John W., Major, Anthony, Beach, Thomas G., Adler, Charles H., Merchant, Kalpana, Knierman, Michael D.

“…A robust top down proteomics method is presented for profiling alpha-synuclein species from autopsied human frontal cortex brain tissue from Parkinson's cases…”
Get full text

High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson's disease by Russo, Marco J, Orru, Christina D, Concha-Marambio, Luis, Giaisi, Simone, Groveman, Bradley R, Farris, Carly M, Holguin, Bret, Hughson, Andrew G, LaFontant, David-Erick, Caspell-Garcia, Chelsea, Coffey, Christopher S, Mollon, Jennifer, Hutten, Samantha J, Merchant, Kalpana, Heym, Roland G, Soto, Claudio, Caughey, Byron, Kang, Un Jung

“…Alpha-synuclein seed amplification assays (αSyn-SAAs) are promising diagnostic tools for Parkinson's disease (PD) and related synucleinopathies. They enable…”
Get full text

Genome-wide RNAseq study of the molecular mechanisms underlying microglia activation in response to pathological tau perturbation in the rTg4510 tau transgenic animal model by Wang, Hong, Li, Yupeng, Ryder, John W, Hole, Justin T, Ebert, Philip J, Airey, David C, Qian, Hui-Rong, Logsdon, Benjamin, Fisher, Alice, Ahmed, Zeshan, Murray, Tracey K, Cavallini, Annalisa, Bose, Suchira, Eastwood, Brian J, Collier, David A, Dage, Jeffrey L, Miller, Bradley B, Merchant, Kalpana M, O'Neill, Michael J, Demattos, Ronald B

“…Activation of microglia, the resident immune cells of the central nervous system, is a prominent pathological hallmark of Alzheimer's disease (AD). However,…”
Get full text

A user's guide for α‐synuclein biomarker studies in biological fluids: Perianalytical considerations by Mollenhauer, Brit, Batrla, Richard, El‐Agnaf, Omar, Galasko, Douglas R., Lashuel, Hilal A., Merchant, Kalpana M., Shaw, Lesley M., Selkoe, Dennis J., Umek, Robert, Vanderstichele, Hugo, Zetterberg, Henrik, Zhang, Jing, Caspell‐Garcia, Chelsea, Coffey, Chris, Hutten, Samantha J., Frasier, Mark, Taylor, Peggy

“…Parkinson's disease biomarkers are needed to increase diagnostic accuracy, to objectively monitor disease progression and to assess therapeutic efficacy as…”
Get full text

Translating glutamate: from pathophysiology to treatment by Javitt, Daniel C, Schoepp, Darryle, Kalivas, Peter W, Volkow, Nora D, Zarate, Carlos, Merchant, Kalpana, Bear, Mark F, Umbricht, Daniel, Hajos, Mihaly, Potter, William Z, Lee, Chi-Ming

“…The neurotransmitter glutamate is the primary excitatory neurotransmitter in mammalian brain and is responsible for most corticocortical and corticofugal…”
Get more information

Reply to: “Could Blood Hexosylsphingosine Be a Marker for Parkinson's Disease Linked with GBA1 Mutations”? by Surface, Matthew, Balwani, Manisha, Waters, Cheryl, Haimovich, Alexander, Gan‐Or, Ziv, Marder, Karen S., Hsieh, Tammy, Song, Linxia, Padmanabhan, Shalini, Hsieh, Frank, Merchant, Kalpana M., Alcalay, Roy N.

Get full text

Reply to: No Evidence that Glucosylsphingosine Is a Biomarker for Parkinson Disease by Surface, Matthew, Balwani, Manisha, Waters, Cheryl, Haimovich, Alexander, Gan‐Or, Ziv, Marder, Karen S., Hsieh, Tammy, Song, Linxia, Padmanabhan, Shalini, Hsieh, Frank, Merchant, Kalpana M., Alcalay, Roy N.

Get full text

BrainSeq: Neurogenomics to Drive Novel Target Discovery for Neuropsychiatric Disorders by Schubert, Christian R., O’Donnell, Patricio, Quan, Jie, Wendland, Jens R., Xi, Hualin S., Winslow, Ashley R., Domenici, Enrico, Essioux, Laurent, Kam-Thong, Tony, Airey, David C., Calley, John N., Collier, David A., Wang, Hong, Eastwood, Brian, Ebert, Philip, Liu, Yushi, Nisenbaum, Laura, Ruble, Cara, Scherschel, James E., Smith, Ryan Matthew, Qian, Hui-Rong, Merchant, Kalpana, Didriksen, Michael, Matsumoto, Mitsuyuki, Saito, Takeshi, Brandon, Nicholas J., Cross, Alan J., Wang, Qi, Manji, Husseini, Kolb, Hartmuth, Furey, Maura, Drevets, Wayne C., Shin, Joo Heon, Jaffe, Andrew E., Jia, Yankai, Straub, Richard E., Deep-Soboslay, Amy, Hyde, Thomas M., Kleinman, Joel E., Weinberger, Daniel R.

“…We outline an ambitious project to characterize the genetic and epigenetic regulation of multiple facets of transcription in distinct brain regions across the…”
Get full text

A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein by Merchant, Kalpana M, Cedarbaum, Jesse M, Brundin, Patrik, Dave, Kuldip D, Eberling, Jamie, Espay, Alberto J, Hutten, Samantha J, Javidnia, Monica, Luthman, Johan, Maetzler, Walter, Menalled, Liliana, Reimer, Alyssa N, Stoessl, A Jon, Weiner, David M

“…The convergence of human molecular genetics and Lewy pathology of Parkinson's disease (PD) have led to a robust, clinical-stage pipeline of alpha-synuclein…”
Get more information

Collaboration and knowledge integration for successful brain therapeutics - lessons learned from the pandemic by Loza, Maria Isabel, Hmeljak, Julija, Bountra, Chas, Audia, James E, Chowdhury, Sohini, Weiman, Shannon, Merchant, Kalpana, Blanco, Maria-Jesus

“…Brain diseases are a major cause of death and disability worldwide and contribute significantly to years of potential life lost. Although there have been…”
Get full text

Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders by Schadt, Eric E, Buchanan, Sean, Brennand, Kristen J, Merchant, Kalpana M

“…A disruptive approach to therapeutic discovery and development is required in order to significantly improve the success rate of drug discovery for central…”
Get full text

Pharmacological characterisation of ligand- and voltage-gated ion channels expressed in human iPSC-derived forebrain neurons by Dage, Jeffrey L., Colvin, Ellen M., Fouillet, Antoine, Langron, Emily, Roell, William C., Li, Jingling, Mathur, Sachin X., Mogg, Adrian J., Schmitt, Matthew G., Felder, Christian C., Merchant, Kalpana M., Isaac, John, Broad, Lisa M., Sher, Emanuele, Ursu, Daniel

“…Introduction Genetic causes, or predisposition, are increasingly accepted to be part of the ethiopathogenesis of many neuropsychiatric diseases. While genes…”
Get full text

Gain and Loss of Function of P2X7 Receptors: Mechanisms, Pharmacology and Relevance to Diabetic Neuropathic Pain by Ursu, Daniel, Ebert, Philip, Langron, Emily, Ruble, Cara, Munsie, Leanne, Zou, Wei, Fijal, Bonnie, Qian, Yue-Wei, McNearney, Terry A, Mogg, Adrian, Grubisha, Olivera, Merchant, Kalpana, Sher, Emanuele

“…Background: Genetic causes of exaggerated or reduced pain sensitivity in humans are well known. Recently, single nucleotide polymorphisms (SNPs) in the gene…”
Get full text

Phosphodiesterase 10A inhibitor, MP-10 (PF-2545920), produces greater induction of c-Fos in dopamine D2 neurons than in D1 neurons in the neostriatum by Wilson, Jonathan M., Ogden, Ann Marie L., Loomis, Sally, Gilmour, Gary, Baucum, Anthony J., Belecky-Adams, Teri L., Merchant, Kalpana M.

“…Studies described here tested the hypothesis that phosphodiesterase 10A inhibition by a selective antagonist, MP-10, activates the dopamine D2 receptor…”
Get full text